Purchase this article with an account.
J. Yoken, R.J. Glatzer, B.S. Taney, L.S. Halperin, W.S. Thompson, P.E. Rubsamen, S.R. Anagnoste; Analysis of Visual Acuity and Anatomic Results Following Intra–Vitreal Injection of Avastin for Subfoveal Choroidal Neovascularization Secondary to Exudative Age Related Macular Degeneration . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5250.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the visual and anatomic results of patients receiving intra–vitreal Avastin for exudative age related macular degeneration (ARMD).
Subjects were selected from our patient population who were currently receiving treatment for subfoveal choroidal neovascularization(CNV). Subtypes of CNV included in the study were predominately classic, minimally classic and occult. At the start of the study period, patients were receiving either Macugen or photodynamic therapy with or without intra–vitreal Kenalog. Patients who were experiencing documented visual decline and persistent or worsening fluid on optical coherence tomography (OCT) and/or increased leakage or size of CNV on fluorescein angiography (FA) were given the option of receiving intra–vitreal Avastin injection. Patient's subsequent vision and anatomic results on clinical exam, OCT and FA, are noted at 1, 3 and 6 months.
Visual acuity and anatomic results including changes on clinical exam, OCT and FA are noted at 1, 3 and 6 months.
Intra–vitreal Avastin may benefit some patients experiencing vision loss while undergoing conventional therapy for subfoveal choriodal neovascularization related to ARMD.
This PDF is available to Subscribers Only